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Objectives. Most developmental processes are under the control of small regulatory RNAs called microRNAs (miRNAs). We
hypothesize that different fetal developmental processes might be reflected by extracellular miRNAs in maternal plasma and may
be utilized as biomarkers for the noninvasive prenatal diagnosis of chromosomal aneuploidies. In this proof-of-concept study, we
report on the identification of extracellular miRNAs in maternal plasma of Down syndrome (DS) pregnancies. Methods. Using
high-throughput quantitative PCR (HT-qPCR), 1043 miRNAs were investigated in maternal plasma via comparison of seven DS
pregnancies with age and fetal sex matched controls. Results. Six hundred and ninety-five miRNAs were identified. Thirty-six
significantly differentially expressed mature miRNAs were identified as potential biomarkers. Hierarchical cluster analysis of these
miRNAs resulted in the clear discrimination of DS from euploid pregnancies. Gene targets of the differentially expressed miRNAs
were enriched in signaling pathways such as mucin type-O-glycans, ECM-receptor interactions, TGF-beta, and endocytosis, which
have been previously associated with DS. Conclusions. miRNAs are promising and stable biomarkers for a broad range of diseases
and may allow a reliable, cost-efficient diagnostic tool for the noninvasive prenatal diagnosis of DS.
1. Introduction
Chromosomal aneuploidy is a main cause of human prenatal
and postnatal morbidity and mortality and the main genetic
cause of mental retardation. The most common aneuploidy
amongst live-borns is Trisomy 21, phenotypically manifested
as Down syndrome (DS) [1]. Down syndrome occurs in
approximately 1 in 700 live births worldwide, with the
incidence rising with advanced maternal age [1]. Prenatal
testing for trisomy’s is currently available to women of
advanced maternal age, with ultrasound findings consistent
with DS or with previous fetuses afflicted with chromosomal
abnormalities [2]. A small but measurable risk of fetal loss
is associated with prenatal diagnostic invasive procedures
[3]. Therefore, there exists a salient necessity to develop
noninvasive aneuploidy screening tests with a high level of
sensitivity and a negligible rate of false positives.
The demonstration of the presence of fetal nucleic acids
in maternal peripheral blood has raised great interest in
the field of noninvasive prenatal diagnostics (NIPD) [4].
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Circulating cell-free fetal DNA (ccfDNA) molecules have
been detected in maternal plasma from the first trimester
onwards, with concentrations that increase with progressing
gestational age [5, 6]. Subsequently, placental-specific cell-
free mRNAs species have been detected in maternal plasma
[7]. Cell-free nucleic acids have led to the development of
a number of NIPD tests such as the determination of fetal
Rhesus D status in Rhesus D negative women [3, 8, 9], sex-
linked diseases [10], and 𝛽-thalassemia [11]. Furthermore,
quantitative aberrations of fetus-derived mRNA transcripts
have been shown in conditions such as preeclampsia [12].
These findings suggest that the detection of circulating fetal
nucleic acids holds much promise for NIPD [13, 14].
Recent studies on microRNAs (miRNAs) suggest that
they might represent yet another class of promising molec-
ular markers [15–17]. miRNAs are a family of small, 18–
22-nucleotide-long, non-protein-coding RNAs that have
emerged as key posttranscriptional regulators of gene expres-
sion [14]. miRNAs interact with their target coding mRNA
to inhibit protein synthesis by either degradation of the
mRNAs or blocking translationwithout degrading the targets
[18]. In mammals, miRNAs are predicted to control the
activity of ∼50% of all protein-coding genes, and functional
studies indicate that miRNAs participate in the regula-
tion of almost every cellular process investigated [14, 19].
Recent data demonstrate that miRNAs play a fundamental
role in diverse biologic and pathologic processes which
include cell proliferation, differentiation, apoptosis, animal
development, carcinogenesis, cardiovascular disease, and
primary muscular disorders [20–22]. miRNAs have been
demonstrated to be highly stable in whole blood, making
them an ideal candidate for noninvasive diagnostic purposes
[23].
The overexpression of 10 miRNAs in the human hip-
pocampus and heart from foetuses with DS, including
the HSA-21 encoded miRNAs HSA-MIR-99a, -HSA-let-7c,
-HSA-MIR-125b-2, HSA-MIR-155, and HSA-MIR-802, has
been reported [24]. In a DS mouse model, HSA-MIR-155
was also found to be overexpressed [25]. However, the results
from Kuhn and coworkers have been recently retracted.
Based on these findings and prior to the retraction, Kotlabova
and colleagues investigated the reliability of these fiveHSA-21
derived miRNAs and although HSA-MIR-155 was also found
to be differentially expressed, they reported that miRNAs do
not represent suitable biomarkers for the NIPD of DS [26].
A wide range of organ systems are affected in DS individ-
uals, some being congenital whereas others are progressive
and include cardiac malformations, craniofacial and skele-
tal anomalies, increased frequency of childhood leukemia,
varying degrees of intellectual disability, and central nervous
system abnormalities [27]. With the assumption that ∼50%
of all genes are miRNA-controlled [19], we hoped to iden-
tify DS-specific miRNA profiles in maternal plasma. High-
throughput quantitative PCR (HT-qPCR) was applied for
the highly accurate and reproducible quantification of 1043
miRNAs in quadruplicate. For the first time, here we report
on a subset miRNAs inmaternal plasma for the identification
of DS. These findings may have great impact on the NIPD of
DS in the future.
What Is Known/What Is New. Differentially expressed miR-
NAshave been previously demonstrated in aDown syndrome
(DS)mousemodel. Extracellular cell-freemiRNAs have been
identified resulting in the distinction of DS from euploid
fetuses. The identified miRNAs counteract with known DS
pathomechanisms reconfirming their specificity for DS.
2. Materials and Methods
2.1. Study Group and Sample Preparation. Blood samples
collected in EDTA were obtained from pregnant women
for whom invasive genetic testing was recommended due
to increased maternal age or suspicious ultrasound findings.
Prenatal ultrasound examination was performed in Berlin
at the Prenatal Diagnosis and Human Genetics Centre
Friedrichstrasse and at the practice of Dr. O¨mer Kilavuz,
which included nuchal translucency measurement for the
risk calculation of Trisomy 21. Blood withdrawal was per-
formed prior to the invasive procedure. Invasive diagnostics
were performed in accordance with routine procedures of
the Practice for Human Genetics Friedrichstrasse by conven-
tional chromosome analysis (karyotyping). In this proof-of-
concept study, plasma from seven Trisomy 21 pregnancies
and seven appropriately matched controls (similar maternal
age, identical gestational week and fetal gender) was selected
(Table 1). Our study was approved by the ethics committee of
the Charite´ (ethics number EA1/262/10), with all participants
providing written consent.
2.2. MicroRNA Isolation. Blood samples were processed
within 24 h followingwithdrawal. To harvest cell-free plasma,
samples were spun at 2,000 rcf for 5min. Plasma was then
transferred to a clean tube followed by centrifugation at
14,000 rcf for 10min to remove cell debris. Samples were
frozen at −80∘C until further use. For HT-qPCR, miRNAs
were isolated from 200𝜇L plasma with the miRNeasy Mini
Kit (Qiagen, Hilden, Germany) using a modified protocol. In
brief, 750 𝜇L fresh QIAzol master mix (800 𝜇L QIAzol and
1.25 𝜇L 0.8 𝜇g/mLMS2RNAper sample) was added, followed
by incubation at RT for 5min. Following the addition of
200𝜇L chloroform, samples were incubated for 2min at RT,
followed by centrifugation for 15min at 12,000 rcf at 4∘C.
Further preparation of the miRNA samples was performed
according to the manufacturer’s instructions. DNase diges-
tion is generally not required since the combined QIAzol
and RNeasy technologies efficiently removemost of the DNA
without DNase treatment. Concentrations were measured
with the Agilent 2100 Bioanalyzer using small RNA chips
(Agilent, CA, USA). As human plasma samples contain only
low amounts of extracellular cell-free RNA, glycogen (Roche,
Germany) was applied as carrier RNA to enhance extraction
efficiency and yields.
2.3. High-Throughput Quantitative PCR (HT-qPCR). High-
throughput quantitative PCR (HT-qPCR) was performed on
individual samples using the SmartChip Human miRNA
Panel V3.0 (WaferGen, CA, USA) in accordance with
the manufacturer’s instructions. The SmartChip Human
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Table 1: Study design and patient characteristics.
Sample Group Maternal age [years] Week of gestation Fetal gender Additional notes
1
Trisomy 21 fetuses
36 12 + 1 Female increased NT
2 43 13 + 3 Female NT 5.1
3 35 19 + 0 Female AV canal
4 37 13 + 3 Male NT 4.2
5 34 13 + 3 Male NT 7.5, hem
6 42 13 + 4 Male NT 6.6
7 44 13 + 6 Female NT 6.6, Softmarker
Matches to 1
Euploid fetuses
42 13 + 1 Female —
Matches to 2 41 13 + 0 Female —
Matches to 3 42 17 + 0 Female —
Matches to 4 40 13 + 3 Male —
Matches to 5 31 13 + 3 Male —
Matches to 6 41 14 + 2 Male —
Matches to 7 35 13 + 5 Female —
NextGeneration Sequencingwas performed on pooled samples in order to identify allmiRNAs that could be of importance, whereas sampleswere subsequently
individually investigated by HT-qPCR.
Abbreviations: NT: nuchal translucency; AV canal: atrioventricular canal defect; hem: hemolytic plasma.
miRNA Panel V3.0 simultaneously quantitatively measures
the expression of the most disease-relevant 1043 human
microRNA species in quadruplicate. Polyadenylation of
miRNA (100 ng) was performed using a modified protocol
of the A-Plus Poly(A) Polymerase Tailing Kit (Epicentre,
WI, USA). Polyadenylation was performed by incubation
at 37∘C for 30min, followed by a 5min denaturation step
at 70∘C. The miRNA templates were reverse transcribed to
cDNA using an anchored oligo(dT)-containing primer. RT-
PCR was performed by incubating the samples at 40∘C for
60min, followed by a denaturation step for 5min at 80∘C.
Quantitative real-time PCRs were performed on SmartChip
Human miRNA Panel v3.0 and the SmartChip Cycler with
the following thermal profile: polymerase activation for 6min
at 95∘C and preamplification for 60 s at 50∘C, followed by 39
cycles comprising 95∘C for 60 s and 60∘C for 70 seconds. A
no template control (NTC) was also performed.
2.4. Bioinformatical and Statistical Analysis. HT-qPCRanaly-
sis was performedusing both qBase Software (Biogazelle, Bel-
gium) and BioConductor (HT-qPCR Package). The Wafer-
Gen qPCR Software report generated provides a short
overview on raw data (replicates) Cqs, distance between
sample andNTC, and normalized relative quantities (NRQs).
These data were also used as a template for downstream anal-
ysis using R and Bioconductor. Data export was recomputed
for each sample with the SmartChip qPCR Software to export
RMDL data for the qBase Software. This tool which uses
individual Cq data and takes into account the flagging system
by the SmartCycler software was used for quality control,
normalization using the “global mean on common targets,”
NTC correction, group comparison, and error propagation.
Data analysis was performed using different strategies based
on Cq values and normalized relative quantities (NRQs). Cqs
values with delta Cqs < 2 were flagged and Cqs values
with delta Cqs < 3.3 were termed “marginal.” Additionally,
Cq values equaling 0 were flagged. Finally, clustering and
classification were performed on standard R functions which
were adjusted to the data sets. A 𝑃 value <0.05 was termed as
statistically significant.
2.5. Predicted miRNA Targets of Differentially Expressed miR-
NAs. In order to identify predictedmiRNA targets, theDiana
mirPath tool V2 was used, which also enables follow-up
analysis, such as mapping target genes on KEGG pathways.
For DianamirPath database, the default MicroT cut-off value
of 0.8 was applied. A merged 𝑃 value is calculated for each
pathway by applying Fisher’s meta-analysis method. The
resulting 𝑃 value depicts the probability that the examined
pathway is significantly enriched with gene targets of at least
one selected miRNA.
3. Results
3.1. Identification of Trisomy 21-Associated miRNAs Using
HT-qPCR. Seven samples from DS pregnancies and seven
matched controls (Table 1) were analyzed in quadruplicate
for 1043 mature miRNAs using the WaferGen miRNA
SmartChip V3. Three hundred and forty-eight miRNAs
which were flagged in all samples were excluded from
downstream analysis, resulting in a remaining 695 miRNAs.
For statistical analysis, data were filtered to include miRNAs
that were identified in at least seven of the 14 samples,
remaining in 328 miRNAs. Raw data, normalized to global
mean data (GN) as well as quantile normalized data (QN),
were investigated on the corrected threshold cycle (Cqs rep-
resenting Ct values minus background fluorescence of the no
template control) and normalized relative quantities (NRQs)
for downstream bioinformatical algorithms. Comparison of
the relative expression of thesemiRNAs was performed using
different strategies (raw Cqs, GN Cqs, QN Cqs, raw NRQs,
and GN NRQs) resulting in the identification of 36 mature
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Table 2: List of 36 potential biomarkers identified to be significantly differentially expressed by HT-qPCR.
Number MicroRNA Mean Ct of DS Mean Ct of control ΔCts Expression in DS relative tocontrol 𝑃 value
1
Commonly identified
by Cqs and NRQs
HSA-MIR-512-5P 30.97 33.66 −2.69 Overrepresented 0.00861
2 HSA-MIR-483-5P 31.80 33.82 −2.02 Overrepresented 0.00454
3 HSA-MIR-888-3P 30.58 34.67 −4.09 Overrepresented 0.00428
4 HSA-MIR-3676-3P 33.30 31.23 2.08 Underrepresented 0.03754
5 HSA-MIR-3918 27.66 28.39 −0.73 Overrepresented 0.02360
6 HSA-MIR-500A-5P 30.58 31.40 −0.82 Overrepresented 0.02986
7 HSA-MIR-30C-5P 27.05 28.07 −1.02 Overrepresented 0.04203
8 HSA-MIR-200C-3P 32.21 30.53 1.69 Underrepresented 0.04393
9 HSA-MIR-627 33.36 31.97 1.40 Underrepresented 0.04518
10
Identified by Cqs only
HSA-MIR-5893P 31.40 33.86 −2.46 Overrepresented 0.00283
11 HSA-MIR-181A-3P 33.55 30.79 2.75 Underrepresented 0.01864
12 HSA-MIR-362-5P 31.94 34.54 −2.60 Overrepresented 0.02495
13 HSA-MIR-518C-5P 31.35 35.04 −3.69 Overrepresented 0.01990
14 HSA-MIR-3667-5P 30.69 33.21 −2.52 Overrepresented 0.02596
15 HSA-MIR-195-3P 29.35 30.58 −1.23 Overrepresented 0.03372
16 HSA-MIR-124-5P 31.72 33.32 −1.60 Overrepresented 0.03635
17 HSA-MIR-498 34.42 31.45 2.98 Underrepresented 0.02934
18 HSA-MIR-18B-3P 30.71 33.30 −2.59 Overrepresented 0.04078
19 HSA-MIR-1249 26.72 29.20 −2.48 Overrepresented 0.04587
20 HSA-MIR-93-5P 25.76 24.76 1.00 Underrepresented 0.00944
21 HSA-MIR-20A-5P 25.04 24.27 0.77 Underrepresented 0.01837
22 HSA-MIR-4328 32.22 31.25 0.97 Underrepresented 0.02078
23 HSA-MIR-92A-3P 22.95 22.10 0.85 Underrepresented 0.02647
24 HSA-MIR-92B-3P 27.65 26.78 0.88 Underrepresented 0.02926
25 HSA-MIR-3652 30.62 31.64 −1.02 Overrepresented 0.02994
26 HSA-MIR-25-3P 24.19 23.42 0.77 Underrepresented 0.03759
27 HSA-MIR-623 33.77 31.63 2.13 Underrepresented 0.03945
28 HSA-MIR-3195 23.11 24.60 −1.49 Overrepresented 0.04885
29
Identified by NRQs
only
HSA-MIR-423-5P 0.87 1.22 −0.35 Underrepresented 0.02007
30 HSA-MIR-27B-3P 1.41 0.85 0.57 Overrepresented 0.03759
31 HSA-MIR-3135a 1.56 0.66 0.91 Overrepresented 0.04044
32 HSA-MIR-486-5P 0.83 1.66 −0.83 Underrepresented 0.02598
33 HSA-MIR-3180-5P 0.71 1.17 −0.46 Underrepresented 0.04036
34 HSA-MIR-629-5P 0.81 1.62 −0.81 Underrepresented 0.04457
35 HSA-MIR-155-5P 0.93 1.89 −0.96 Underrepresented 0.04712
36 HSA-MIR-3907 0.80 1.46 −0.65 Underrepresented 0.04983
NRQs: normalized relative quantities; Cq: Ct values subtracted by background; GN: raw data, normalized to global mean data; QN: quantile normalized data;
DS: Down syndrome.
miRNAs, which were found to be significantly differentially
expressed in DS pregnancies in comparison to the euploid
pregnant cohort (Table 2 and Supplement 1 available online
at http://dx.doi.org/10.1155/2014/402475). NinemiRNAswere
identified as common elements by both Cq and NRQ values,
whereas 19 miRNAs were identified only by Cq values and
eight only by NRQs.
3.2. Identification of Subsets of miRNAs Differentiating
between Down Syndrome and Euploid Pregnancies. Although
a particular trend of some miRNAs can be observed, a single
miRNA that discriminatedDS fromeuploid pregnancies does
not exist (Figure 1). Using the full set of miRNAs, a particular
miRNA signature allowing for the differentiation betweenDS
and euploid pregnancies was not detected (data not shown).
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Figure 1: Column plots of selected miRNAs representing an expression profile between Down syndrome versus euploid pregnancies.
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Figure 2: Clustering based on the global normalized Cqs of the 20 most differentially expressed microRNAs (a) and even clustering based
on the raw NRQs of only the 10 most differentially expressed miRNAs (b) were performed. As demonstrated here, clustering can be archived
that distinguishes Down syndrome from euploid pregnancies utilizing a subset of 10–20miRNAs. Sample identification comprised of: sample
ID number.fetal sex.week of gestation.group. Abbreviations: f = female, m = male, T = Trisomy 21, N = normal.
However, by using a subset of 10 or 20 miRNAs that were
most significantly differentially expressed in raw NRQs and
GN Cqs, respectively, a clear separation of both groups was
observed (Figure 2).
3.3. MicroRNA Target Prediction. In order to assess our
hypothesis that there are distinct differences in the develop-
ment of DS fetuses which may be reflected by aberrations
in the miRNA profile in maternal plasma, miRNA target
prediction was performed. Using the Diana mirPath tool
(V2), all 36 miRNAs identified by HT-qPCR were annotated
in this database. The a priori approach (union of genes)
revealed the identification of 46 significantly enriched path-
ways (Supplement 2). In order to increase the stringency of
the target pathway prediction, a posteriori approach (path-
way union) was also applied resulting in the enrichment
of the KEGG gene ontology terms mucin type O-glycan
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Table 3: Gene ontology categories of predicted miRNA targets
(pathway union).
KEGG pathway 𝑃 value # genes # miRNAs
Mucin type O-glycan
biosynthesis 4.06𝐸 − 13 8 4
ECM-receptor
interaction 1.55𝐸 − 09 16 7
Glycosaminoglycan
biosynthesis-
chondroitin
sulphate
9.73𝐸 − 05 2 2
TGF-beta signaling
pathway 0.00039237 30 8
Endocytosis 0.00145435 49 6
Presented are KEGG GO terms for the 36 differentially expressed mature
miRNAs identified byHT-qPCR (Table 2).Here, the results of pathway union
are presented. The full list of GO terms identified by at least one miRNA
is presented in Supplement 2. Pathways that have already been previously
associatedwithDown syndromepathologieswere identified.These primarily
include the mucin type O-glycan biosynthesis (related to 𝛽-HCG), ECM-
receptor interactions, and TGF-𝛽 signaling.
#: number of.
biosynthesis, ECM-receptor interactions, glycosaminoglycan
biosynthesis (chondroitin sulphate), TGF-𝛽 signaling, and
endocytosis (Table 3, Supplement 2).
4. Discussion
A wide range of organ systems are affected in Down syn-
drome individuals, with some being congenital whereas
others are progressive, and include cardiac malformations,
increased frequency of childhood leukemia, and varying
degrees of mental retardation [27]. miRNAs are considered
to play an active role in the regulation of developmental
processes. Differentially expressed miRNAs have been previ-
ously demonstrated in a DS mouse model [25, 28]. With the
assumption that approximately 50% of all genes are miRNA-
controlled [19], we were able to identify DS-specific miRNA
profiles in maternal plasma (Table 2).
In accordance with Kotlabova and colleagues [26], the
miRNAs reported by Kuhn and colleagues (except miR-155)
were not found to be differentially expressed in our study.
However, developmental dysregulation is rather complex and
also involves miRNAs encoded on other chromosomes, thus
requiring comprehensive HT qPCR profiling technologies to
identify these differences. We identified miR-155 to be dif-
ferentially expressed, although underrepresented in DS preg-
nancies in comparison with control cohorts. Hromadnı´kova´
and colleagues identified this miRNA to be significantly
elevated in the plasma of pregnant women compared to
nonpregnant controls [29]. A recent study described the iden-
tification of miRNA by small RNA sequencing in DS fetuses
[30]. Several miRNAs were commonly found including
HSA-MIR483-5p, HSA-MIR-486-5p, HSA-MIR-92b, HSA-
MIR-181a, and HSA-MIR-155, although expression patterns
differed in the first two miRNAs. A direct comparison of
both studies is not possible due to numerous differences
in the study designs including different input material,
sample preparation, clinical numbers, and the application
of Next Generation Sequencing (NGS) instead of qPCR-
based quantifications. Next Generation Sequencing requires
normalization and library preparation steps that altermiRNA
profiles, making downstream validation studies using qPCR
necessary.
Here we describe the potential use of miRNA patterns
for diagnostic purposes. When using 10 or 20 miRNAs that
were found to be the most differentially expressed, a clear
identification of DS was possible (Figure 2). However, the
crosslink between miRNA expression patterns and various
pathways that may be dysregulated in DS settings is via the
identification of predicted miRNA targets. The advantage
of the Diana mirPath tool is that miRNA targets were
experimentally validated. An additional distinctive feature of
this tool is the follow-up analysis that enables the evaluation
of target genes for enrichment amongst KEGG pathways. By
evaluating all 36 miRNAs in the Diana mirPath tool, the
detected KEGG pathways accurately reflected many known
pathomechanisms of DS.
The mucin type O-glycan biosynthesis was found to
be the most significantly enriched KEGG pathway using
pathway union (Table 2). Human chorionic gonadotropin
(HCG) is a glycoprotein hormone produced by placental
trophoblasts and trophoblastic tumors [31]. The antibody
B152 whichmainly recognizes the core-2 O-glycans at Ser-132
has been demonstrated to be useful in the prediction of DS
pregnancies [32]. Heat map analysis connecting miRNAwith
KEGG pathways via the clustering of significance revealed
that mucin type O-glycan is closely related to HSA-MIR-498,
HSA-MIR-30C-5P, HSA-MIR-629-5P, and HSA-MIR-195-3P.
Interestingly, HSA-MIR-498 has been found to be expressed
in the human placenta, preferentially in the cytoplasm of
syncitiotrophoblasts [33], whereas HSA-MIR-30C has been
found in human fetal liver [34], providing additional evidence
for a fetal origin of these miRNAs.
The second most significantly enriched GO term identi-
fied in this study was ECM-receptor interaction. Grossman
and colleagues studied the effect of the coexpression of
DSCAM and COL6A2, interaction partners that are over-
expressed in DS patients and are associated with cardiomy-
opathy [35]. In their study, the gene expression profile of
cooverexpression versus normal expression also revealed the
KEGG gene ontology terms ECM-receptor interaction as the
most significant pathway. Furthermore, they identified the
GO categories “pathways in cancer,” “arrhythmogenic right
ventricular cardiomyopathy,” “regulation of actin cytoskele-
ton,” “axon guidance,” “dilated cardiomyopathy,” “focal adhe-
sion,” and “hypertrophic cardiomyopathy (HCM),” whereas
all these pathways were also identified to be significantly
enriched in our study using the “genes union” approach of
the Diana mirPath tool (Supplement 2).
Glycosaminoglycans (GAGs) are associated with mental
retardation and multiple organ failure and already serve
as biomarkers in prenatal diagnostics. This pathway was
identified due to the strong linkage of HSA-MIR-362 and
HSA-MIR-124. Interestingly, HSA-MIR-362 has been asso-
ciated with fetal teratogenesis and mental retardation in
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Figure 3: Hypothesized mechanisms on the entrance of fetal/placental miRNAs in the maternal circulation. (a) Connection of the mother
and fetus via the placenta. (b) Chorionic villi are responsible for sustaining the placenta with nutrients and oxygen. The intervillus space is
filled withmaternal blood. (c) Cellular release mechanisms and extracellular transportation systems of miRNAs in accordance with Creemers
and colleagues [40]. In the cytoplasm, miRNAs can be incorporated into small vesicles, exosomes, which stem from the endosome, and are
released from cells when multivesicular bodies coalesce with the plasma membrane. Microvesicles may also be the source of cytoplasmic
miRNAs, which are released from the cell via plasmamembrane blebbing. miRNAs are also found in circulation in a microparticle-free form.
These miRNAs can be associated with high-density lipoproteins or bound to RNA-binding proteins such as Ago2. It remains unknown as to
how these miRNA-protein complexes are released from the cell. They have been suggested to be passively released, as by-products of dead
cells, or in an active miRNA-specific manner, via interaction with specific membrane channels or proteins.
mice [36], suggesting its relevance in neurogenerative disease.
HSA-MIR-124 in addition to HSA-MIR-498, HSA-MIR-20A,
and HSA-MIR-629 were found to be associated with DS
via a computational approach of human miRNA disease
association [37]. Abnormal TGF-𝛽 has been associated with
plaque formation in the brains of Alzheimer’s disease and DS
patients [38]. Moreover, abnormal TGF-𝛽 levels have been
identified in the amniotic fluid of DS pregnancies [39]. These
findings provide evidence that the differentially expressed
miRNAs in this study are not randomly identified due to the
low sample number but point towards its strong linkage to
many well-known DS pathomechanisms.
Although differential expression patterns of miRNAs can
be observed between DS and euploid pregnancies, the exact
transport mechanisms of extracellular, cell-free miRNAs into
the maternal circulation remain unknown. Several possible
mechanisms have been described [40] (Figure 3), although
the underlying reason for the release of Trisomy 21-specific
miRNAs remains speculative. Trisomy 21 leads to a dysregu-
lation of gene expression including miRNAs. These miRNAs
may then enhance the dysregulation of genes in a genome-
wide manner, resulting in mild or severe symptoms, depend-
ing on the dysregulation. Cells have been demonstrated to
select some miRNAs for cellular release while others are
retained [41]. Their exocytosis may represent a protective
mechanism inwhich harmfulmiRNAs are actively enveloped
and secreted out of the cells via exosomes. The Down
syndrome-specific miRNA profile may therefore reflect the
severity of symptoms, for example, in respect to mental
retardation, thus classifying miRNAs as the first prognostic
biomarkers in the NIPD of DS. In contrast to cffDNA, which
is derived from apoptotic placental cells, themiRNA found in
maternal plasma may be of fetal and not of placental origin.
This hypothesis, however, awaits confirmation.
Muchmore effort is required to exploremiRNA functions
in DS. Results demonstrated here have to be confirmed with
a broader cohort to validate the usefulness of miRNAs for
robust noninvasive diagnostic testing. Furthermore, miRNAs
may also allow for antagomiR strategies to cure or at least
partially reduce serious DS symptoms during prenatal and
postnatal development of DS patients. This may result in a
reduction of pregnancy terminations.
Whole and massively parallel genome sequencing have
been applied for the detection of DS [42–46]. In contrast to
cffDNA and in combination with NGS, our method provides
an inexpensive and fast alternative, whereas only chromo-
somal aneuploidies are investigated. Furthermore, results
are readily available within two days. Another advantage is
that a diagnostic test based on qPCR can be developed and
distributed in the form of a kit. We hope that a diagnostic test
based onmiRNAswill be relatively less expensive and covered
by health insurance companies for all women who would like
to obtain a sense of security, which affirms the well-being of
the unborn child.
AlthoughmiRNAs are considered as promising biomark-
ers not only for prenatal diagnostics, alterations of miRNA
expression during pregnancy and other potential pregnancy-
associated complications such as preeclampsia, pregnancy-
associated diabetes, and other maternal diseases should also
be taken into consideration if miRNA patterns are to be
used to identify chromosomal aneuploidies.The use of extra-
cellular cell-free miRNAs for diagnostic purposes may pose
a common problem where particular miRNA biomarkers
are not present in all samples (Figure 1). This significantly
burdens data analysis. In order to stringent statistical analysis,
only miRNAs that have been found in at least seven of the 14
samples were used revealing the loss of half of the identified
miRNAs. Additionally, the quantitative differences of certain
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miRNA biomarkers in plasma samples when comparing
healthy with disease samples are very low.
In conclusion, extracellular cell-free miRNAs have been
identified resulting in the distinction of DS from euploid
fetuses. The identified miRNAs counteract with known
DS pathomechanisms reconfirming their specificity for DS.
miRNAs are highly stable in blood and exhibit potential
use for NIPD of DS. Furthermore, miRNAs may represent
prognostic markers for the characterisation of the severity
of DS disabilities and may allow for antagoMir strategies in
“treating” DS features in the future. Due to the low sample
number in this proof-of-concept study, these findings can
only be considered as promising and as an avenue for further
research.
Disclosure
Julian Kamhieh-Milz, Gu¨rkan Bal, and Abdulgabar Salama
have applied for a patent based on the results of this study
(WO2014114802 A1).
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Funding
This project was funded by the Stiftung Charite´, who was
not involved in the study design, data collection and analysis,
paper preparation, and/or publication decisions.
Acknowledgments
The authors acknowledge Dr. Futam Samman and Dr.
O¨mer Kilavuz for providing valuable samples. They thank
Professor Neitzel for her assistance in the ethics applica-
tion and Adjunct Professor Markus Stumm for his criti-
cal review of the paper. HT-qPCR was performed by the
Integrated Blood Biobank of Luxemburg (IBBL). Julian
Kamhieh-Milz is the recipient of an Innovation Prize (2011)
from the Stiftung Charite´, which funded this project. Dr.
Matthias Futschik acknowledges funding from the Por-
tuguese Fundac¸a˜o para a Cieˆncia e a Tecnologia (PEst-
OE/EQB/LA0023/2013, IF/00881/2013).
References
[1] A.Me´garbane´, A. Ravel, C.Mircher et al., “The 50th anniversary
of the discovery of trisomy 21: the past, present, and future
of research and treatment of Down syndrome,” Genetics in
Medicine, vol. 11, no. 9, pp. 611–616, 2009.
[2] W. I. Cohen, “Health care guidelines for individuals with Down
Syndrome,” Down Syndrome Quarterly, vol. 4, no. 3, pp. 1–16,
1999.
[3] R. W. K. Chiu, C. R. Cantor, and Y. M. D. Lo, “Non-invasive
prenatal diagnosis by single molecule counting technologies,”
Trends in Genetics, vol. 25, no. 7, pp. 324–331, 2009.
[4] Y.M. Dennis Lo, N. Corbetta, P. F. Chamberlain et al., “Presence
of fetal DNA in maternal plasma and serum,” The Lancet, vol.
350, no. 9076, pp. 485–487, 1997.
[5] Y. M. D. Lo, “Fetal DNA in maternal plasma: biology and
diagnostic applications,” Clinical Chemistry, vol. 46, no. 12, pp.
1903–1906, 2000.
[6] Y. M. D. Lo, “Recent advances in fetal nucleic acids in maternal
plasma,” Journal of Histochemistry and Cytochemistry, vol. 53,
no. 3, pp. 293–296, 2005.
[7] L. L. Poon, T. N. Leung, T. K. Lau, and Y. M. Lo, “Presence of
fetal RNA in maternal plasma,” Clinical Chemistry, vol. 46, no.
11, pp. 1832–1834, 2000.
[8] Y. M. Lo, N. M. Hjelm, C. Fidler et al., “Prenatal diagnosis of
fetal RhD status by molecular analysis of maternal plasma,”The
NewEngland Journal ofMedicine, vol. 339, no. 24, pp. 1734–1738,
1998.
[9] B. H.W. Faas, E. A. Beuling, G. C. M. L. Christiaens, A. E. G. K.
Von Dem Borne, and C. E. Van Der Schoot, “Detection of fetal
RHD-specific sequences in maternal plasma,” The Lancet, vol.
352, no. 9135, p. 1196, 1998.
[10] J.-M. Costa, A. Benachi, and E. Gautier, “New strategy for
prenatal diagnosis of X-linked disorders,” The New England
Journal of Medicine, vol. 346, no. 19, article 1502, 2002.
[11] R. W. K. Chiu, T. K. Lau, T. N. Leung, K. C. K. Chow, D.
H. K. Chui, and Y. M. Dennis Lo, “Prenatal exclusion of 𝛽
thalassaemia major by examination of maternal plasma,” The
Lancet, vol. 360, no. 9338, pp. 998–1000, 2002.
[12] E. K. O. Ng, T. N. Leung, N. B. Y. Tsui et al., “The concen-
tration of circulating corticotropin-releasing hormone mRNA
in maternal plasma is increased in preeclampsia,” Clinical
Chemistry, vol. 49, no. 5, pp. 727–731, 2003.
[13] E. K. O. Ng, A. El-Sheikhah, R. W. K. Chiu et al., “Evaluation
of human chorionic gonadotropin𝛽-subunitmRNAconcentra-
tions in maternal serum in aneuploid pregnancies: a feasibility
study,” Clinical Chemistry, vol. 50, no. 6, pp. 1055–1057, 2004.
[14] S. S. C. Chim, T. K. F. Shing, E. C.W.Hung et al., “Detection and
characterization of placental microRNAs in maternal plasma,”
Clinical Chemistry, vol. 54, no. 3, pp. 482–490, 2008.
[15] W. M. Grady and M. Tewari, “The next thing in prognostic
molecular markers: MicroRNA signatures of cancer,” Gut, vol.
59, no. 6, pp. 706–708, 2010.
[16] V. Kinet, J. Halkein, E. Dirkx, and L. J. deWindt, “Cardiovascu-
lar extracellular microRNAs: emerging diagnostic markers and
mechanisms of cell-to-cell RNA communication,” Frontiers in
Genetics, vol. 4, article 214, 2013.
[17] P. Jarolim, “Overview of cardiac markers in heart disease,”
Clinics in Laboratory Medicine, vol. 34, no. 1, pp. 1–14, 2014.
[18] T. Du and P. D. Zamore, “microPrimer: the biogenesis and
function ofmicroRNA,”Development, vol. 132, no. 21, pp. 4645–
4652, 2005.
[19] J. Krol, I. Loedige, and W. Filipowicz, “The widespread reg-
ulation of microRNA biogenesis, function and decay,” Nature
Reviews Genetics, vol. 11, no. 9, pp. 597–610, 2010.
[20] X. M. Zhu, T. Han, I. L. Sargent, G. W. Yin, and Y. Q. Yao,
“Differential expression profile ofmicroRNAs in humanplacen-
tas from preeclamptic pregnancies vs normal pregnancies,”The
American Journal of Obstetrics and Gynecology, vol. 200, no. 6,
pp. 661.e1–661.e7, 2009.
[21] N. Bushati and S. M. Cohen, “MicroRNA functions,” Annual
Review of Cell and Developmental Biology, vol. 23, pp. 175–205,
2007.
BioMed Research International 9
[22] I. Eisenberg, A. Eran, I. Nishino et al., “Distinctive patterns of
microRNA expression in primarymuscular disorders,” Proceed-
ings of the National Academy of Sciences of the United States of
America, vol. 104, no. 43, pp. 17016–17021, 2007.
[23] G. Reid, M. B. Kirschner, and N. van Zandwijk, “Circulating
microRNAs: association with disease and potential use as
biomarkers,” Critical Reviews in Oncology/Hematology, vol. 80,
no. 2, pp. 193–208, 2011.
[24] D. E. Kuhn, G. J. Nuovo, M. M. Martin et al., “Human
chromosome 21-derived miRNAs are overexpressed in down
syndrome brains and hearts,” Biochemical and Biophysical
Research Communications, vol. 436, no. 3, p. 564, 2013.
[25] X.-J. He, Y. Xiao, Q. Zhang, L.-P. Ma, N. Li, and J. Yang, “Detec-
tion and functional annotation of misregulated microRNAs in
the brain of the Ts65Dn mouse model of Down syndrome,”
Chinese Medical Journal, vol. 126, no. 1, pp. 108–113, 2013.
[26] K. Kotlabova, J. Doucha, D. Chudoba, P. Calda, K. Dlouha,
and I. Hromadnikova, “Extracellular chromosome 21-derived
microRNAs in euploid & aneuploid pregnancies,” Indian Jour-
nal of Medical Research, vol. 138, pp. 935–943, 2013.
[27] T. F. Haydar and R. H. Reeves, “Trisomy 21 and early brain
development,” Trends in Neurosciences, vol. 35, no. 2, pp. 81–91,
2012.
[28] J. Keck-Wherley, D. Grover, S. Bhattacharyya et al., “Abnormal
microRNA expression in Ts65Dn hippocampus and whole
blood: contributions to down syndrome phenotypes,” Develop-
mental Neuroscience, vol. 33, no. 5, pp. 451–467, 2011.
[29] I. Hromadnı´kova´, K. Kotlabova´, J. Doucha, D. Chudoba,
P. Calda, and K. Dlouha´, “Extracellular chromosome 21—
derived microRNAs in maternal circulation: evaluation of their
diagnostic potential for screening of Down syndrome,” Ceska
Gynekologie, vol. 77, no. 5, pp. 395–402, 2012.
[30] Y. Xu, W. Li, X. Liu, H. Ma, Z. Tu, and Y. Dai, “Analysis
of microRNA expression profile by small RNA sequencing in
down syndrome fetuses,” International Journal of Molecular
Medicine, vol. 32, no. 5, pp. 1115–1125, 2013.
[31] E. V. Chandrasekaran, J. Xue, J. Xia et al., “Mammalian sialyl-
transferase ST3Gal-II: its exchange sialylation catalytic prop-
erties allow labeling of sialyl residues in mucin-type sialylated
glycoproteins and specific gangliosides,” Biochemistry, vol. 50,
no. 44, pp. 9475–9487, 2011.
[32] S. Birken, “Specific measurement of O-linked core 2 sugar-
containing isoforms of hyperglycosylated human chorionic
gonadotropin by antibody B152,” Tumor Biology, vol. 26, no. 3,
pp. 131–141, 2005.
[33] R. Zhang, Y.-Q. Wang, and B. Su, “Molecular evolution of
a primate-specific microRNA family,” Molecular Biology and
Evolution, vol. 25, no. 7, pp. 1493–1502, 2008.
[34] H. Fu, Y. Tie, C. Xu et al., “Identification of human fetal liver
miRNAs by a novel method,” FEBS Letters, vol. 579, no. 17, pp.
3849–3854, 2005.
[35] T. R. Grossman, A. Gamliel, R. J. Wessells et al., “Over-
expression of DSCAM and COL6A2 cooperatively generates
congenital heart defects,” PLoS Genetics, vol. 7, no. 11, Article ID
e1002344, 2011.
[36] L.-L. Wang, Z. Zhang, Q. Li et al., “Ethanol exposure induces
differential microRNA and target gene expression and terato-
genic effects which can be suppressed by folic acid supplemen-
tation,” Human Reproduction, vol. 24, no. 3, pp. 562–579, 2009.
[37] X. Chen,M. X. Liu, andG. Y. Yan, “RWRMDA: predicting novel
human microRNA-disease associations,”Molecular BioSystems,
vol. 8, no. 10, pp. 2792–2798, 2012.
[38] E. A. van der Wal, F. Gomez-Pinilla, and C. W. Cotman,
“Transforming growth factor-𝛽1 is in plaques in Alzheimer and
Down pathologies,” NeuroReport, vol. 4, no. 1, pp. 69–72, 1993.
[39] S. J. Bromage, A. K. Lang, I. Atkinson, and R. F. Searle,
“Abnormal TGF𝛽 levels in the amniotic fluid of Down syn-
drome pregnancies,” The American Journal of Reproductive
Immunology, vol. 44, no. 4, pp. 205–210, 2000.
[40] E. E. Creemers, A. J. Tijsen, and Y. M. Pinto, “Circulating
microRNAs: novel biomarkers and extracellular communica-
tors in cardiovascular disease?” Circulation Research, vol. 110,
no. 3, pp. 483–495, 2012.
[41] L. Pigati, S. C. S. Yaddanapudi, R. Iyengar et al., “Selective release
of MicroRNA species from normal and malignant mammary
epithelial cells,” PLoS ONE, vol. 5, no. 10, Article ID e13515, 2010.
[42] R. W. K. Chiu, K. C. A. Chan, Y. Gao et al., “Noninvasive
prenatal diagnosis of fetal chromosomal aneuploidy by mas-
sively parallel genomic sequencing ofDNA inmaternal plasma,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 105, no. 51, pp. 20458–20463, 2008.
[43] G. J. Liao, K. C. Chan, P. Jiang et al., “Noninvasive prenatal
diagnosis of fetal trisomy 21 by allelic ratio analysis using
targeted massively parallel sequencing of maternal plasma
DNA,” PLoS ONE, vol. 7, no. 5, Article ID e38154, 2012.
[44] D. W. Bianchi, L. D. Platt, J. D. Goldberg, A. Z. Abuhamad,
A. J. Sehnert, and R. P. Rava, “Genome-wide fetal aneuploidy
detection by maternal plasma DNA sequencing,” Obstetrics &
Gynecology, vol. 119, pp. 890–901, 2012.
[45] A. J. Sehnert, B. Rhees, D. Comstock et al., “Optimal detection
of fetal chromosomal abnormalities by massively parallel DNA
sequencing of cell-free fetalDNA frommaternal blood,”Clinical
Chemistry, vol. 57, no. 7, pp. 1042–1049, 2011.
[46] M. Stumm,M. Entezami, N. Trunk et al., “Noninvasive prenatal
detection of chromosomal aneuploidies using different next
generation sequencing strategies and algorithms,” Prenatal
Diagnosis, vol. 32, no. 6, pp. 569–577, 2012.
